ERBB2 and breast cancer: The utility of the G2M pathway score as a biomarker to predict pCR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer is significantly hindered by the fact that it did not correlate with DFS of patients who underwent neoadjuvant chemotherapy in this study.